Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

42 results about "Endothelial lipase" patented technology

Endothelial lipase (LIPG) is a form of lipase secreted by vascular endothelial cells in tissues with high metabolic rates and vascularization, such as the liver, lung, kidney, and thyroid gland. The LIPG enzyme is a vital component to many biological process. These processes include lipoprotein metabolism, cytokine expression, and lipid composition in cells. Unlike the lipases that hydrolyze Triglycerides, endothelial lipase primarily hydrolyzes phospholipids. Due to the hydrolysis specificity, endothelial lipase contributes to multiple vital systems within the body. On the contrary to the beneficial roles that LIPG plays within the body, endothelial lipase is thought of to play a potential role in cancer and inflammation. Knowledge obtained in vitro and in vivo suggest the relations to these conditions, but human interaction knowledge lacks due to the recent discovery of endothelial lipase. Endothelial lipase was first characterized in 1999. The two independent research groups which are notable for this discovery cloned the endothelial lipase gene and identified the novel lipase secreted from endothelial cells. The anti-Atherosclerosis opportunity through alleviating plaque blockage and prospective ability to raise High-density lipoprotein (HDL) have gained endothelial lipase recognition.

Modulation of endothelial lipase expression

Compounds, compositions and methods are provided for modulating the expression of endothelial lipase. The compositions comprise oligonucleotides, targeted to nucleic acid encoding endothelial lipase. Methods of using these compounds for modulation of endothelial lipase expression and for diagnosis and treatment of disease associated with expression of endothelial lipase are provided.
Owner:IONIS PHARMA INC

Oxadiazole derivative having endothelial lipase inhibitory activity

Provided is a compound useful as an endothelial lipase inhibitor. The compound is a compound represented by formula (I), a pharmaceutically acceptable salt thereof, or a solvate of either. In formula (I), ring A is an aromatic carbocycle or an aromatic heterocycle; Z is -NR5-, -O-, or -S-; R5 is a hydrogen atom, an (un)substituted alkyl, an (un)substituted aryl, etc.; R1 is a hydrogen atom, a halogen atom, hydroxy, cyano, nitro, carboxy, an (un)substituted alkyl, etc.; R2 and R3 each independently is a hydrogen atom, a halogen atom, hydroxy, etc.; R4 is a group represented by the formula -(CR6R7)n-R8 (wherein R6 and R7 each independently is a hydrogen atom, a halogen atom, hydroxy, etc., n is an integer of 0-3, and R8 is carboxy, cyano, an (un)substituted alkyl, etc.); RX is a halogen atom, hydroxy, cyano, nitro, carboxy, an (un)substituted alkyl, etc.; and m is an integer of 0-3.
Owner:SHIONOGI & CO LTD

Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors

The present invention provides compounds of Formula (I) or Formula (III): [INSERT CHEMICAL STRUCTURE HERE] (I) [INSERT CHEMICAL STRUCTURE HERE] (III) as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.
Owner:BRISTOL MYERS SQUIBB CO

Functionalized furan-2-sulfonamides exhibiting endothelial lipase inhibition

InactiveUS20160257672A1Low HDL-C levelLow HDL-COrganic chemistryCardiovascular disorderFuranCoronary artery disease
The present invention relates to pharmaceutical compositions comprising furan-2-sulfonamide derivatives. The present invention further relates to methods of treatment of diseases or conditions associated with endothelial lipase activity, including coronary artery disease and low HDL-C.
Owner:TEMPLE UNIVERSITY +1

Modulation of endothelial lipase expression

Compounds, compositions and methods are provided for modulating the expression of endothelial lipase. The compositions comprise oligonucleotides, targeted to nucleic acid encoding endothelial lipase. Methods of using these compounds for modulation of endothelial lipase expression and for diagnosis and treatment of disease associated with expression of endothelial lipase are provided.
Owner:IONIS PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products